Antitumour imidazotetrazines: past, present... and future?

被引：1
|
作者：
Stevens, Malcolm F. G. [1 ]
Wheelhouse, Richard T. [2 ]
机构：
[1] Univ Nottingham, Sch Pharm, Biodiscovery Inst, Nottingham NG7 2RD, England
[2] Univ Bradford, Sch Pharm & Med Sci, Inst Canc Therapeut, Bradford BD7 1DP, England
来源：
RSC CHEMICAL BIOLOGY | 2023年 / 4卷 / 10期
关键词：
DRUG TEMOZOLOMIDE; MISMATCH REPAIR; PHASE-I; MITOZOLOMIDE; CHEMISTRY; DNA; METHYLTRANSFERASE; RESISTANCE; MECHANISM; PRODRUGS;
D O I：
10.1039/d3cb00076a
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
It is 40 years since the publication of the patent that announced the imidazotetrazines temozolomide and mitozolomide to the world and 30 since the discovery that they function as prodrugs of alkyldiazonium reactive intermediates. Temozolomide combined with radiation is established as the first-line treatment for glioma but despite the attentions of the inventors and others, further examples of this intriguing ring system have yet to enter the clinic.
引用
收藏
页码：736 / 741
页数：7
相关论文
共 50 条
12345